Juliet Preston
May 16, 2017
A new report by GlobalData has underscored the extreme blockbuster potential of fatty liver disease and non-alcoholic steatohepatitis (NASH), projecting that the current $618 million market will balloon to $25.3 billion by 2026.
A new report by research and consulting firm GlobalData has underscored the extreme blockbuster potential of non-alcoholic steatohepatitis (NASH).
Looking at the seven major markets (7MM) of the U.S., France, Germany, Italy, Spain, the U.K., and Japan, the authors determined that the field would expand at a compound annual growth rate (CAGR) of 45 percent.
That means that during the next 10 years, the field is projected to swell forty-fold from $618 million in 2016 to $25.3 billion in 2026.